@misc{misc, title  = {{33781 Sustained and durable response up to 24 weeks after last dose observed in a phase 2a study (NCT03754309) of amlitelimab (KY1005, SAR445229) a novel nondepleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD)}},

 url = {{}},

 year = {{2022}},

 month = {{9}},

 author = {{Weidinger S and Bieber T and Cork M and Reich A and Brennan N and Quaratino S and Wilson R and Porter-Brown B}},

 note = {{Accessed on 2024/12/22}}}